Pfizer Extends Patent Protection for Rare Disease Drug Tafamidis
Pfizer has reached settlements with three drug manufacturers to extend the patent life of tafamidis, a key ingredient in its rare disease drug Vyndamax. The settlements delay the entry of generic versions until early next decade, ensuring stable U.S. sales through 2031. The company had previously warned of a potential revenue decline after 2028.
Tickers: $PFE
Topics: generic competition patent extension pharmaceutical litigation rare disease drug